Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- CMIC MPSS to Offer Comprehensive Region-Wide CSO Service for Long-Listed Drugs
November 30, 2012
- China’s Drug Costs to Expand to 11 Trillion Yen in 2030 by 5% Annual Growth: UtoBrain
November 29, 2012
- Long-Listed Products to Be Switched to Combination Drugs, Original Drugs Rather than Generics: President Sawai
November 29, 2012
- Sawai to Seek Alternative Suppliers for All of Its Products
November 29, 2012
- Santen Files Anti-Allergic Ophthalmic Solution DE-114
November 29, 2012
- Chugai, Nippon Shinyaku Conclude Codevelopment, Comarketing Agreement for Anti-CD20 Antibody
November 29, 2012
- Takeda to Establish Medical Affairs Department within Development Division
November 28, 2012
- Approximately 30% of Doctors Conduct ALK Gene Test in All Patients: Pfizer Survey
November 28, 2012
- Pfizer Launches Glycylcycline Antibiotic Tygacil
November 27, 2012
- 8 Companies’ Entries to COPD Market Turn It into Red Ocean
November 27, 2012
- Bayer Eyes Sales of €3 Billion in Japan by 2017: Chairman Dekkers
November 27, 2012
- Health Professionals Voice Concerns over JPMA Transparency Guidelines
November 26, 2012
- Teva Pharma to Temporarily Discontinue Marketing of Risperidone Generics Due to Halt in Bulk Drug Production
November 26, 2012
- Fuji Pharma, Mochida Receive Approvals for Biosimilar Gran
November 26, 2012
- Decline in Sales of Long-listed Drugs Continues with a Double-punch from Generics, NHI Price Reductions
November 26, 2012
- Joint Venture with Actavis to Continue Operations: ASKA Pres. Yamaguchi
November 22, 2012
- Astellas Submits Supplemental NDA in US for Tarceva
November 22, 2012
- MSD to Promote Joint Detailing by Sales Units Specialized in Different Therapeutic Fields: Vice Pres. Kotani
November 22, 2012
- Bayer to Initiate PIII Study of Xarelto for Prevention of MACE in Patients with CAD/PAD, Considers Study in Japan as Well
November 22, 2012
- Japanese Ethical Drug Market Shows Negative Growth in July-September for the First Time in 7 Quarters: IMS Japan
November 21, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…